Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174795 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
A Phase 1 study of Urinary Tract Infections, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 14
- Study locations
NCT03174795 is a Phase 1 study of Urinary Tract Infections that has completed, run by Hoffmann-La Roche. The registered enrollment target is 20 participants, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 3 states.
The verdict
NCT03174795, a Phase 1 study of Urinary Tract Infections, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.
Conditions Studied
Interventions
- DRUG RO7079901
- DRUG Meropenem
Study Locations (14)
Other
- Semmelweis University, First Dept of Medicine - Budapest
- Szent Imre Egyetemi Oktatokorhaz - Budapest
- Kenezy Gyula Korhaz-Rend. Eges. Szol.; Klinikai Farm. Infek. es Allerg. Intezet - Debrecen
- Liepaja Regional hospital - Liepāja
- P.Stradina Kliniska Uni Tes Slimnica; Latvian Center of Nephrology - Riga
- Riga East clinical university hospital - Riga
- Klinika Urologii Ogólnej: Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu; Urology - Bydgoszcz
- Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek - Lodz
- Szpital Kliniczny Dzieciątka Jezus; Oddział Urologii - Warsaw
- Clinical Center of Serbia; Clinic of Urology - Belgrade
- Clinical Center Zemun - Belgrade
- Clinical Hospital Center Bezanijska Kosa - Belgrade
California
- eStudySite - La Mesa
Florida
- Jacksonville Center For Clinical Research - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2017-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03174795
The ClinicalTrials.gov registry entry for NCT03174795 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (96% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which RO7079901 is the first listed.
NCT03174795 reports 14 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03174795 about?
NCT03174795 is a clinical study titled "A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection". This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.
What is the current status of trial NCT03174795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-07-11. Estimated completion is 2017-12-16.
What conditions does trial NCT03174795 study?
This clinical trial studies the following conditions: Urinary Tract Infections.
What interventions are being tested in trial NCT03174795?
The interventions under investigation include: RO7079901 (DRUG), Meropenem (DRUG).
Who is sponsoring clinical trial NCT03174795?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03174795 being conducted?
This trial has 14 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
Treatment and/or Prevention of Urinary Tract Infections
COMPLETED · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
NextGen - Clinical Implication of Next Generation Sequencing
RECRUITING · Phase 4
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.